Yahoo Finance The Worldwide Carrier Screening Industry is Expected to Reach $3.64 Billion by 2030
Global Carrier Screening Market
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Carrier Screening Market Share, Size, Trends, Industry Analysis Report, By Type; By Medical Condition; By Technology; By End-User; By Regions; Segment Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global carrier screening market size is expected to reach USD 3.64 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
The well-established healthcare infrastructure and the rise in innovative product introductions are driving the expansion of the industry. Many countries concentrate their efforts on developing enhanced medical infrastructure that includes enhanced treatment techniques.
Furthermore, developed-country nations have modern healthcare infrastructure integrated with various transmission methods, pushing the rise and need for these techniques throughout such countries. Many people wish to discover if their genetic or inherited disorders might be transmitted to their offerings. As a result, these factors are expected to open up promising growth opportunities for companies in the overall industry during the forecasted period.
Additionally, the increasing prevalence of fetal chromosomal abnormalities boosts industry growth. According to the WHO, congenital abnormalities are major causes of fetal and infant mortality, chronic illness, and disabilities. Every year, an estimated 295 000 newborns nationwide die within 28 days of birth due to congenital abnormalities. Thus, the rising prevalence of fetal abnormalities, increasing product launches, and established healthcare infrastructure propel the industry growth during the forecast period.
Based on the type, the expanded segment accounted for the leading share in the industry in 2021. Customized panel testing and predesigned panel testing are the extended segment components. Due to advancements in DNA sequencing, polymerase chain reaction, metabolomics, and other technologies, the expanded sector accounted for most of the global market share in 2021.
Market players such as Abbott Laboratories, 23Andme Inc., Autogenomics Inc., Danaher Corporation, Fulgent Genetics Inc., Eurofins Scientific, Illumina Inc., Luminex Corporation, Invitae Corporation, MedGenome, Natera Inc., Myriad Genetics, Opko Health, Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Roche AG, Sequenom Inc., and True Health. are some key players operating in the global market.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Research Methodology
4. Global Carrier Screening Market Insights
4.1. Carrier Screening - Industry Snapshot
4.2. Carrier Screening Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Increasing emphasis on early disease detection & prevention
4.2.1.2. Increasing awareness of carrier screening
4.2.2. Restraints and Challenges
4.2.2.1. High cost of service
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Carrier Screening Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Carrier Screening Market, by Medical Condition
5.1. Key Findings
5.2. Introduction
5.2.1. Global Carrier Screening Market, by Medical Condition, 2018 - 2030 (USD Billion)
5.3. Pulmonary Conditions
5.3.1. Global Carrier Screening Market, by Pulmonary Conditions, by Region, 2018 - 2030 (USD Billion)
5.4. Hematological Conditions
5.4.1. Global Carrier Screening Market, by Hematological Conditions, by Region, 2018 - 2030 (USD Billion)
5.5. Neurological Conditions
5.5.1. Global Carrier Screening Market, by Neurological Conditions, by Region, 2018 - 2030 (USD Billion)
5.6. Other Conditions
5.6.1. Global Carrier Screening Market, by Other Conditions, by Region, 2018 - 2030 (USD Billion)
6. Global Carrier Screening Market, by Type
6.1. Key Findings
6.2. Introduction
6.2.1. Global Carrier Screening Market, by Type, 2018 - 2030 (USD Billion)
6.3. Expanded
6.3.1. Global Carrier Screening Market, by Expanded, by Region, 2018 - 2030 (USD Billion)
6.3.2. Customized Panel Testing
6.3.2.1. Global Carrier Screening Market, by Customized Panel Testing, by Region, 2018 - 2030 (USD Billion)
6.3.3. Predesigned Panel Testing
6.3.3.1. Global Carrier Screening Market, by Predesigned Panel Testing, by Region, 2018 - 2030 (USD Billion)
6.4. Targeted Disease
6.4.1. Global Carrier Screening Market, by Targeted Disease, by Region, 2018 - 2030 (USD Billion)
7. Global Carrier Screening Market, by Technology
7.1. Key Findings
7.2. Introduction
7.2.1. Global Carrier Screening Market, by Technology, 2018 - 2030 (USD Billion)
7.3. DNA Sequencing
7.3.1. Global Carrier Screening Market, by DNA Sequencing, by Region, 2018 - 2030 (USD Billion)
7.4. Polymerase Chain Reaction
7.4.1. Global Carrier Screening Market, by Polymerase Chain Reaction, by Region, 2018 - 2030 (USD Billion)
7.5. Microarrays
7.5.1. Global Carrier Screening Market, by Microarrays, by Region, 2018 - 2030 (USD Billion)
7.6. Other Technologies
7.6.1. Global Carrier Screening Market, by Other Technologies, by Region, 2018 - 2030 (USD Billion)
8. Global Carrier Screening Market, by End-User
8.1. Key Findings
8.2. Introduction
8.2.1. Global Carrier Screening Market, by End-User, 2018 - 2030 (USD Billion)
8.3. Hospitals
8.3.1. Global Carrier Screening Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
8.4. Reference Laboratories
8.4.1. Global Carrier Screening Market, by Reference Laboratories, by Region, 2018 - 2030 (USD Billion)
8.5. Physician Offices & Clinics
8.5.1. Global Carrier Screening Market, by Physician Offices & Clinics, by Region, 2018 - 2030 (USD Billion)
8.6. Other End Users
8.6.1. Global Carrier Screening Market, by Other End Users, by Region, 2018 - 2030 (USD Billion)
9. Global Carrier Screening Market, by Geography
10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
11.1. 23Andme Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Recent Development
11.2. Abbott Laboratories
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Benchmarking
11.2.4. Recent Development
11.3. Autogenomics Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Benchmarking
11.3.4. Recent Development
11.4. Danaher Corporation
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Benchmarking
11.4.4. Recent Development
11.5. Eurofins Scientific
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Benchmarking
11.5.4. Recent Development
11.6. Fulgent Genetics Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Benchmarking
11.6.4. Recent Development
11.7. Illumina Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Benchmarking
11.7.4. Recent Development
11.8. Invitae Corporation
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Benchmarking
11.8.4. Recent Development
11.9. Luminex Corporation
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Benchmarking
11.9.4. Recent Development
11.10. MedGenome
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Benchmarking
11.10.4. Recent Development
11.11. Myriad Genetics
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Benchmarking
11.11.4. Recent Development
11.12. Natera Inc.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Benchmarking
11.12.4. Recent Development
11.13. Opko Health
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Benchmarking
11.13.4. Recent Development
11.14. Quest Diagnostics Incorporated
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Benchmarking
11.14.4. Recent Development
11.15. Roche AG
11.15.1. Company Overview
11.15.2. Financial Performance
11.15.3. Product Benchmarking
11.15.4. Recent Development
11.16. Sequenom Inc.
11.16.1. Company Overview
11.16.2. Financial Performance
11.16.3. Product Benchmarking
11.16.4. Recent Development
11.17. Thermo Fisher Scientific Inc.
11.17.1. Company Overview
11.17.2. Financial Performance
11.17.3. Product Benchmarking
11.17.4. Recent Development
11.18. True Health
11.18.1. Company Overview
11.18.2. Financial Performance
11.18.3. Product Benchmarking
11.18.4. Recent Development
For more information about this report visit https://www.researchandmarkets.com/r/v417l0
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
